Drug Trial Radar · NCT00444925
Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)
Last checked: Nov 20, 2026Latest source record: Mar 24, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,712
Actual
Start
Apr 2007
Primary completion
Jul 2008
Study completion Jul 2008
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Mar 8, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of fesoterodine in comparison to tolterodine and placebo for overactive bladder
Conditions
- Overactive Bladder
Interventions
fesoterodine fumarateDrug
4 mg once daily (OD) for 1 week followed by a forced dose-escalation to 8 mg once daily (OD) for 11 weeks
placeboDrug
once daily (OD)for 12 weeks
tolterodine tartrateDrug
4 mg once daily (OD) for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12 (End of Treatment).Time frame: Baseline, Week 12
Locations
178 sites in 29 countries. Site status is shown where the registry gives one.
Pfizer Investigational Site
Homewood, Alabama
Pfizer Investigational Site
Huntsville, Alabama
Pfizer Investigational Site
Mobile, Alabama
Pfizer Investigational Site
Carmichael, California
Pfizer Investigational Site
Orangevale, California
Pfizer Investigational Site
San Diego, California
Pfizer Investigational Site
Aurora, Colorado
Pfizer Investigational Site
Waterbury, Connecticut
Pfizer Investigational Site
Miami, Florida
Pfizer Investigational Site
Wellington, Florida
Pfizer Investigational Site
Atlanta, Georgia
Pfizer Investigational Site
Coeur d'Alene, Idaho
Pfizer Investigational Site
Sandpoint, Idaho
Pfizer Investigational Site
Aurora, Illinois
Pfizer Investigational Site
West Des Moines, Iowa
Pfizer Investigational Site
Newton, Kansas
Pfizer Investigational Site
Shrevport, Louisiana
Pfizer Investigational Site
Watertown, Massachusetts
Pfizer Investigational Site
Chaska, Minnesota
Pfizer Investigational Site
Lawrenceville, New Jersey
Pfizer Investigational Site
Albuquerque, New Mexico
Pfizer Investigational Site
Garden City, New York
Pfizer Investigational Site
Mineola, New York
Pfizer Investigational Site
Burlington, North Carolina
Pfizer Investigational Site
Concord, North Carolina
Pfizer Investigational Site
Huntersville, North Carolina
Pfizer Investigational Site
Dayton, Ohio
Pfizer Investigational Site
Allentown, Pennsylvania
Pfizer Investigational Site
Allentown, Pennsylvania
Pfizer Investigational Site
Pittsburgh, Pennsylvania
Pfizer Investigational Site
Pittsburgh, Pennsylvania
Pfizer Investigational Site
East Providence, Rhode Island
Pfizer Investigational Site
Charleston, South Carolina
Pfizer Investigational Site
Columbia, South Carolina
Pfizer Investigational Site
Kingsport, Tennessee
Pfizer Investigational Site
Milan, Tennessee
Pfizer Investigational Site
Houston, Texas
Pfizer Investigational Site
Provo, Utah
Pfizer Investigational Site
Chesapeake, Virginia
Pfizer Investigational Site
Seattle, Washington
Showing 40 of 178 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.